CIK 0001935979 · Large accelerated filer
Biohaven Ltd.
Sign in to watch- Ticker
- BHVN
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Virgin Islands, British
- Entity type
- operating
- Phone
- 203-404-0410
- Business address
- 215 CHURCH STREET, NEW HAVEN, CT, 06510
- Former names
- Biohaven Research Ltd.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-08 | Coric Vlad Chief Executive Officer | Grant or award | +2,162 | 1,666,234 | ||
| 2024-03-08 | Coric Vlad Chief Executive Officer | Grant or award | +2,155 | 840,659 | ||
| 2024-03-08 | Coric Vlad Chief Executive Officer | Grant or award | +2,155 | 406,982 | ||
| 2024-01-08 | CHILDS JOHN W Director | Other acquisition | +48,505 | 2,160,168 | ||
| 2024-01-08 | Coric Vlad Chief Executive Officer | Grant or award | +5,400 | 1,662,431 | ||
| 2024-01-08 | Coric Vlad Chief Executive Officer | Grant or award | +5,384 | 838,504 | ||
| 2024-01-08 | Coric Vlad Chief Executive Officer | Grant or award | +5,384 | 404,827 | ||
| 2024-01-02 | Clark George C. VP, Chief Accounting Officer | Grant or award · Stock Options (Right to buy) | +27,500 | 27,500 | ||
| 2024-01-02 | Car Bruce Chief Scientific Officer | Grant or award · Stock Options (Right to buy) | +96,250 | 96,250 | ||
| 2024-01-02 | Gentile Kimberly SVP, Clinical Operations | Grant or award · Stock Options (Right to buy) | +96,250 | 96,250 | ||
| 2024-01-02 | Buten Matthew Chief Financial Officer | Grant or award · Stock Options (Right to buy) | +96,250 | 96,250 | ||
| 2024-01-02 | Coric Vlad Chief Executive Officer | Grant or award · Stock Options (Right to buy) | +275,000 | 275,000 | ||
| 2023-12-29 | Antonijevic Irina Director | Option exercise | +11,000 | 13,535 | ||
| 2023-12-29 | Antonijevic Irina Director | Sale | −11,000 | $41.79 | $460K | 2,535 |
| 2023-12-29 | Antonijevic Irina Director | Option exercise · Stock Options (Right to Buy) | −11,000 | 114,000 | ||
| 2023-11-02 | Buten Matthew Chief Financial Officer | Grant or award · Stock Options (Right to buy) | +78,750 | 78,750 | ||
| 2023-11-02 | Coric Vlad Chief Executive Officer | Grant or award · Stock Options (Right to buy) | +225,000 | 225,000 | ||
| 2023-11-02 | Clark George C. VP, Chief Accounting Officer | Grant or award · Stock Options (Right to buy) | +22,500 | 22,500 | ||
| 2023-11-02 | Gentile Kimberly SVP, Clinical Operations | Grant or award · Stock Options (Right to buy) | +78,750 | 78,750 | ||
| 2023-11-02 | Car Bruce Chief Scientific Officer | Grant or award · Stock Options (Right to buy) | +78,750 | 78,750 |
Page 6 of 18 · 355 trades